Hydralazine also inhibits angiogenesis (a finding from both in vitro and animal studies [58]) by suppressing vascular endothelial growth factor and basic fibroblast growth factor signaling, both of which are correlated with the clinicopathological features of myeloproliferative neoplasms [59] and MM [60]. The gene discussed is VEGFA; the disease is Miyoshi myopathy.